Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 369Carcinoma, Non-Small-Cell Lung 315Neoplasms 289Prostatic Neoplasms 245Colorectal Neoplasms 214Multiple Myeloma 182Lung Neoplasms 170Neoplasm Metastasis 152Leukemia, Myeloid, Acute 137Pancreatic Neoplasms 130Squamous Cell Carcinoma of Head and Neck 127Ovarian Neoplasms 117Melanoma 98Carcinoma, Renal Cell 94Recurrence 87Stomach Neoplasms 81Precursor Cell Lymphoblastic Leukemia-Lymphoma 80Carcinoma, Hepatocellular 80Lymphoma, Non-Hodgkin 79Head and Neck Neoplasms 79Lymphoma 78Glioblastoma 78Triple Negative Breast Neoplasms 76Lymphoma, Large B-Cell, Diffuse 75Urinary Bladder Neoplasms 69Endometrial Neoplasms 68Brain Neoplasms 68Leukemia, Lymphocytic, Chronic, B-Cell 65Uterine Cervical Neoplasms 62Lymphoma, Follicular 62

Interventions

niraparib 1Prednisone 1Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Metastatic Castration-sensitive Prostate Cancer × 30 days × Clear all
NCT04497844 2026-05-11

AMPLITUDE

Janssen Research & Development, LLC

Phase 3 Active not recruiting
696 enrolled 15 charts 1 FDA
Genitourinary

Metastatic Castration-sensitive Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡